Emicizumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Emicizumab |
| DrugBank ID | DB13923 |
| Brand Names (EU) | Hemlibra |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.99% |
Approved Indication (EMA)
Hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency): with factor VIII inhibitors without factor VIII inhibitors who have: severe disease (FVIII < 1%) moderate disease (FVIII ? 1% and ? 5%) with severe bleeding phenotype. Hemlibra can be used in all age groups.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | pseudo-von Willebrand disease | 99.99% | DL |
| 2 | primary release disorder of platelets | 99.99% | DL |
| 3 | Glanzmann thrombasthenia | 99.98% | DL |
| 4 | hemophilia | 99.94% | DL |
| 5 | Scott syndrome | 99.92% | DL |
| 6 | acquired coagulation factor deficiency | 99.90% | DL |
| 7 | bleeding diathesis due to a collagen receptor defect | 99.86% | DL |
| 8 | hemorrhagic disorder due to a constitutional thrombocytopenia | 99.85% | DL |
| 9 | symptomatic form of hemophilia in female carriers | 99.79% | DL |
| 10 | thrombotic thrombocytopenic purpura | 99.61% | DL |
| 11 | fetal and neonatal alloimmune thrombocytopenia | 99.52% | DL |
| 12 | flood factor deficiency | 99.40% | DL |
| 13 | hereditary thrombocytosis with transverse limb defect | 99.27% | DL |
| 14 | familial thrombomodulin anomalies | 99.27% | DL |
| 15 | inherited thrombophilia | 99.25% | DL |
| 16 | platelet-type bleeding disorder | 99.22% | DL |
| 17 | hemophilia A with vascular abnormality | 99.02% | DL |
| 18 | methylcobalamin deficiency type cblG | 98.95% | DL |
| 19 | Ehlers-Danlos syndrome, fibronectinemic type | 98.82% | DL |
| 20 | factor XI deficiency | 98.73% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.